AC Immune SA (ACIU)
2.63
-0.05
(-1.87%)
USD |
NASDAQ |
Sep 18, 16:00
2.65
+0.02
(+0.76%)
After-Hours: 20:00
AC Immune Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | -0.3277M |
| September 30, 2025 | -0.3378M |
| June 30, 2025 | -0.3237M |
| March 31, 2025 | -0.287M |
| December 31, 2024 | -0.2112M |
| September 30, 2024 | -0.2361M |
| June 30, 2024 | -0.0423M |
| March 31, 2024 | -0.7869M |
| December 31, 2023 | 46.23M |
| September 30, 2023 | 0.5414M |
| June 30, 2023 | 2.126M |
| March 31, 2023 | -0.1524M |
| December 31, 2022 | -0.1601M |
| September 30, 2022 | -0.1452M |
| June 30, 2022 | -0.0994M |
| March 31, 2022 | -0.9915M |
| December 31, 2021 | 31.12M |
| September 30, 2021 | 4.638M |
| June 30, 2021 | -0.0618M |
| March 31, 2021 | 8.506M |
| December 31, 2020 | -0.5156M |
| Date | Value |
|---|---|
| September 30, 2020 | 0.1263M |
| June 30, 2020 | -0.113M |
| March 31, 2020 | -0.3862M |
| December 31, 2019 | -0.207M |
| September 30, 2019 | 0.7241M |
| June 30, 2019 | -0.8059M |
| March 31, 2019 | 50.40M |
| December 31, 2018 | -1.827M |
| September 30, 2018 | 111.52M |
| June 30, 2018 | 0.144M |
| March 31, 2018 | 0.0011M |
| December 31, 2017 | 0.126M |
| September 30, 2017 | 0.056M |
| June 30, 2017 | 0.0636M |
| March 31, 2017 | 0.0289M |
| December 31, 2016 | -4.627M |
| September 30, 2016 | 69.74M |
| June 30, 2016 | 13.94M |
| March 31, 2016 | -0.3803M |
| December 31, 2015 | 27.98M |
| September 30, 2015 | 0.0329M |
Cash From Financing Definition
Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Precigen, Inc. | -0.033M |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| Aldeyra Therapeutics, Inc. | -15.30M |
| BeOne Medicines Ltd. | -6.128M |
Cash from Financing (Quarterly) Related Metrics
| Free Cash Flow Yield | -34.77% |